| 前收市價 | 2.3900 |
| 開市 | 2.4500 |
| 買盤 | 2.3300 x 100 |
| 賣出價 | 3.0400 x 200 |
| 今日波幅 | 2.3500 - 2.4800 |
| 52 週波幅 | 1.9000 - 5.1400 |
| 成交量 | |
| 平均成交量 | 181,015 |
| 市值 | 235.468M |
| Beta 值 (5 年，每月) | 1.01 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.7000 |
| 業績公佈日 | 2024年8月02日 - 2024年8月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 10.62 |
ZacksAbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
ZacksDown -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
InvestorPlacePenny Stock Powerhouses: 7 Picks Poised for Explosive Growth
Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market action during the post-pandemic period. Seemingly, each generation of investors have their special phase with these speculative entities. From a moral perspective, there’s nothing wrong per say about targeting penny stocks for growth. Otherwise, going to Las Vegas and gambling would be considered an u
